Showing 221-230 of 6805 results for "".
Injectable Beauty: New Uses for Dermal Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/injectable-beauty-new-uses-for-dermal-fillers/19766/Today fillers are being used to do more than just chase wrinkles and folds, shares Jeanette Black, MD. Some exciting new uses include biostimulation with Sculptra or hyperdilute Radiesse to addresscellulite and skin laxity along with the use of intradermal hyaluronic acid-based fillers for skin hydrNRS: New Rosacea Classification; Pediatric Teledermatology; Bleach Baths
https://practicaldermatology.com/series/dermwire-tv/nrs-new-rosacea-classification-pediatric-teledermatology-bleach-baths/18394/There's a new standard classification and pathophysiology of rosacea from the National Rosacea Society. New evidence shows that virtual diagnosis of pediatric dermatologic conditions is feasible. New research suggests that water baths may be just as good as bleach baths for treating eczema. ResearchL'Oreal Nabs CeraVe, Smart Beauty Tools, Skin Cancer Knowledge Lacking
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-l-oreal-nabs-cerave-smart-beauty-tools-skin-cancer-knowledge-lacking/18703/Researchers from La Roche-Posay and the George Washington University Department of Dermatology find that citizens in Australia, Ireland, Brazile, and Greece are best educated about UV exposure risks. Americans scored about average, said study author Dr. Adam Friedman. Valeant has agreed to sell itsThe Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market availValeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicCosentyx Approved, Silver is Bad for Burns
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-approved-silver-is-bad-for-burns/18971/FDA approves the first IL-17 inhibitor for psoriasis—Cosentyx from Noavartis, and new research explains why silver sulfadiazine is bad for burn wounds. Plus, we get an update on the Dermatology Summit and the state of innovation in dermatology, and learn about Phase III trials for Dermira's Cimzia.A New Year and New Beginnings
https://practicaldermatology.com/series/the-practical-dermatology-podcast/a-new-year-and-new-beginnings/32417/The Practical Dermatology Podcast relaunches with the latest news to start 2025 and a conversation between Chief Medical Editor Neal Bhatia, MD, FAAD, and new Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD. Dr. Bhatia and Dr. Swanson discuss the new wave of atopic dermatitis therapeuticExperts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvSCALE 2024: Dr. Hilary Baldwin’s Tips and Tricks for Treating Keloids
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-hilary-baldwins-tips-and-tricks-for-treating-keloids/26366/Hilary E. Baldwin, MD, discusses best practices for the treatment of keloids at Music City SCALE.DermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildin